Patents Examined by Myron G. Hill
-
Patent number: 11471524Abstract: In certain embodiments, the disclosure relates to the polynucleotide sequences of respiratory syncytial virus (RSV). In certain embodiments, the disclosure relates to isolated or recombinant nucleic acids and polypeptides comprising desirable nucleic acid sequences and mutations disclosed herein. In certain embodiments, isolated or recombinant RSV comprising the nucleic acids and polypeptides disclosed herein (e.g., attenuated recombinant RSV) are also provided, as are immunogenic compositions including such nucleic acids, polypeptides, and RSV genomes that are suitable for use as vaccines. Attenuated or killed RSV containing these nucleic acids and mutation in the form of copied nucleic acids (e.g., cDNAs) are also contemplated.Type: GrantFiled: September 18, 2020Date of Patent: October 18, 2022Assignees: Emory University, Children's Healthcare of Atlanta, Inc.Inventors: Martin L. Moore, Jia Meng, Anne Hotard, Elizabeth Littauer, Christopher Stobart
-
Patent number: 11464850Abstract: Provided is an antigen including a recombinant respiratory syncytial virus (RSV) F protein, wherein the recombinant RSV F protein includes an antigenic region flanked with an HRN region and an HRC region, and the antigenic region includes one or more antigenic sites selected from the group consisting of site Ø, site II, and site IV. The present disclosure also provides a nucleic acid molecule encoding the antigen and a vaccine composition including the antigen for eliciting an immune response against RSV.Type: GrantFiled: November 22, 2017Date of Patent: October 11, 2022Assignee: National Taiwan UniversityInventors: Limin Huang, Jenmin Huang
-
Patent number: 11459583Abstract: Provided herein are chimeric adenoviral vectors. The provided chimeric adenoviral vectors can be used to induce a protective immune response in a subject.Type: GrantFiled: October 30, 2018Date of Patent: October 4, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Taco Gilles Uil, Soumitra Roy, Jort Vellinga, Selina Khan, Jerome H. Hv. Custers
-
Patent number: 11446374Abstract: The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection.Type: GrantFiled: October 11, 2019Date of Patent: September 20, 2022Assignee: Novavax, Inc.Inventors: Peter M. Pushko, Yingyun Wu, Michael J. Massare, Ye Liu, Gale Smith, Bin Zhou
-
Patent number: 11433130Abstract: The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a Marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting Marek's disease in combination with at least a second disease in poultry.Type: GrantFiled: October 14, 2020Date of Patent: September 6, 2022Assignee: The Texas A&M University SystemInventors: Sanjay M. Reddy, Blanca M. Lupiani
-
Patent number: 11421020Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both RSV, MPV and PVM. The invention also relates to nucleic acids that encode, immortalized B cells and cultured plasma cells that produce, and to polypeptides that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV or MPV infection and RSV and MPV co-infection.Type: GrantFiled: May 27, 2020Date of Patent: August 23, 2022Assignee: HUMABS BIOMED SAInventor: Davide Corti
-
Patent number: 11414675Abstract: A lentiviral vector production system comprises (a) a lentiviral culture supplement to control cell growth, (b) a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, (c) a lentiviral production enhancer comprising sodium propionate, sodium butyrate, and caffeine to boost lentiviral production, wherein the lentiviral vector production system is serum-free. A method of lentiviral vector production comprises using the lentiviral production system. Another method for lentiviral vector production comprises (a) culturing eukaryotic cells in a serum-free medium, (b) providing a lentiviral culture supplement to control cell growth, (c) transfecting the cells with a lentiviral vector using a transfection reagent comprising DHDMS, DOPE, and cholesterol to increase transfection efficiency, and (d) providing a lentiviral production using a lentiviral production enhancer comprising sodium propionate, sodium butyrate capable of boosting lentiviral production.Type: GrantFiled: September 29, 2017Date of Patent: August 16, 2022Assignee: LIFE TECHNOLOGIES CORPORATIONInventors: Xin Yu, Xavier de Mollerat du Jeu
-
Patent number: 11406677Abstract: Human clinical use of a chimeric poliovirus construct has demonstrated excellent anti-tumor effect. The mechanism of action is believed to involve both viral oncolysis as well as immune recruitment, both of which lead to necrosis in the area of the tumor. No adverse effects have been observed.Type: GrantFiled: September 10, 2020Date of Patent: August 9, 2022Assignee: Duke UniversityInventors: Matthias Gromeier, John H. Sampson, Darell D. Bigner, Annick Desjardins, Henry S. Friedman
-
Patent number: 11400051Abstract: The disclosure concerns methods for executing PBV protocols to preserve biopharmaceuticals using a conventional lyophilizer. Also described are steps for maintaining isolation of a biopharmaceuticals for achieving aseptic drying using the conventional lyophilizer. As a collateral benefit, the invention provides good manufacturing practice (GMP) compliant methods for achieving aseptic drying of biopharmaceutical compositions using a conventional lyophilizer disposed outside of a clean-room area. Finally, methods and formulations str disclosed for preserving biopharmaceuticals suitable for mucosal or transdermal delivery to a patient.Type: GrantFiled: July 11, 2018Date of Patent: August 2, 2022Assignee: Universal Stabilization Technologies, Inc.Inventor: Victor Bronshtein
-
Patent number: 11382969Abstract: A pharmaceutical composition comprising at least two peptides of from 15 to 60 amino acids in length, selected from peptides comprising a sequence of at least 15 contiguous amino acids of one of the sequences shown in SEQ ID NOs: 1 to 4 or of a sequence having at least 80% identity to one of the sequences shown in SEQ ID NOs: to 4, wherein each peptide comprises at least one CD8+ T-cell epitope and/or at least one CD4+ T-cell epitope and wherein each peptide elicits a response in peripheral blood mononuclear cells (BMC) from at least one chronically infected HBV individual in an 10 in vitroassay.Type: GrantFiled: May 27, 2019Date of Patent: July 12, 2022Assignee: Altimmune UK LTDInventors: Bertrand Victor Gilbert Georges, Carlton Bradley Brown
-
Patent number: 11376317Abstract: Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Disclosed are nucleic acid sequences capable of encoding peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Also disclosed are methods for eliciting a protective immune response against RSV comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by FcRn; a modified pre-fusion RSV F protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.Type: GrantFiled: August 30, 2018Date of Patent: July 5, 2022Assignee: UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Xiaoping Zhu, Weizhong Li
-
Patent number: 11370829Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.Type: GrantFiled: July 28, 2020Date of Patent: June 28, 2022Assignee: Humabs BioMed SAInventor: Davide Corti
-
Patent number: 11360088Abstract: A method for measuring influenza B virus by an immunoassay, which method enables specific detection of influenza B virus with a higher sensitivity than conventional methods, and a device or a kit therefor are disclosed. The method for measuring influenza B virus includes carrying out an immunoassay of influenza B virus by a sandwich method using two kinds of monoclonal antibodies each of which specifically reacts with the region of the 125th to 248th amino acids of matrix protein (M1) of influenza B virus, which two kinds of monoclonal antibodies are capable of binding to the region of the 125th to 248th amino acids of M1 at the same time, or antigen-binding fragments thereof.Type: GrantFiled: September 10, 2014Date of Patent: June 14, 2022Assignee: DENKA COMPANY LIMITEDInventors: Koichi Inano, Takashi Miyazawa, Osamu Ishikawa
-
Patent number: 11338031Abstract: The present invention relates to novel nucleic acid molecules encoding a pre-fusion RSV F protein or immunologically active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The invention further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).Type: GrantFiled: June 24, 2020Date of Patent: May 24, 2022Assignee: Janssen Vaccines & Prevention B.V.Inventors: Johannes Petrus Maria Langedijk, Janneke M. Verhagen
-
Patent number: 11339376Abstract: Provided is a host cell for stably propagating a virulent hand, foot and mouth disease virus, the host cell expressing no heparan sulfate and overexpressing primate scavenger receptor class B member 2 (SCARB2). Also provided is a method for screening for an anti-hand, foot and mouth disease virus vaccine or an anti-hand, foot and mouth disease virus drug using a stably cultured virulent hand, foot and mouth disease virus.Type: GrantFiled: March 27, 2018Date of Patent: May 24, 2022Assignee: Tokyo Metropolitan Institute of Medical ScienceInventors: Satoshi Koike, Kyousuke Kobayashi, Yui Sudaka, Ayumi Imura
-
Patent number: 11339206Abstract: The present invention relates to compositions and methods for the treatment of immunodeficiency (e.g., primary immunodeficiency disease). In particular, the invention provides human plasma immunoglobulin compositions containing select antibody titers specific for a plurality of respiratory pathogens, methods of identifying human donors and donor samples for use in the compositions, methods of manufacturing the compositions, and methods of utilizing the compositions (e.g., for prophylactic administration and/or therapeutic treatment (e.g., passive immunization (e.g., immune-prophylaxis))).Type: GrantFiled: June 15, 2020Date of Patent: May 24, 2022Assignee: ADMA BIOMANUFACTURING, LLCInventors: Adam S. Grossman, James Mond, Jerrold B. Grossman, Dov A. Goldstein
-
Patent number: 11324816Abstract: Described herein are virus-like particles (VLPs) that display on their surfaces antigenic paramyxovirus (e.g., RSV and/or MPV) proteins. Also described are methods of making and using these VLPs.Type: GrantFiled: August 29, 2016Date of Patent: May 10, 2022Assignee: TechnoVax, Inc.Inventors: Jose M. Galarza, Velasco Cimica, Hélène Boigard
-
Patent number: 11312761Abstract: Anti-RSV antibodies with neutralizing potency against RSV subtype A and RSV subtype B are provided, as well as methods for their identification, isolation, generation, and methods for their preparation and use are provided.Type: GrantFiled: October 20, 2017Date of Patent: April 26, 2022Assignee: Adimab, LLCInventor: Laura M. Walker
-
Patent number: 11305006Abstract: The disclosure relates to the technical field of veterinary biological products, and discloses an avian influenza and fowl adenovirus type 4 bi-combined genetic engineering subunit vaccine. An antigen in the vaccine is a fusion antigen; the fusion antigen has a) avian influenza virus HA protein; b) fowl adenovirus fiber2 protein; c) a specific linker peptide located between the avian influenza virus HA protein and the fowl adenovirus fiber2 protein; the amino acid sequence of the specific linker peptide is as shown in SEQ ID NO:2. This vaccine contains the fusion antigen which can induce poultries to produce a high-level specific antibody to protect poultries from avian influenza and fowl adenovirus infection. Meanwhile, the disclosure also discloses a method for preparing the vaccine.Type: GrantFiled: September 13, 2021Date of Patent: April 19, 2022Assignees: ZHAOQING DAHUANONG BIOLOGY MEDICINE CO., LTD, ZHAOQING INSTITUTE OF BIOTECHNOLOGY CO., LTDInventors: Ruiai Chen, Yanpeng Li, Lianghai Wen, Wenyan Zhang, Jianjun Sun
-
Patent number: 11292830Abstract: The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 includes an amino acid sequence represented by GFTFSNY (SEQ ID NO: 1); the CDR2 includes an amino acid sequence represented by NSGGTG (SEQ ID NO: 2); and the CDR3 includes an amino acid sequence represented by RVDGRVLSTIVVSYDY (SEQ ID NO: 3). The antibody is capable of binding to an intranuclear protein of an influenza virus.Type: GrantFiled: January 14, 2020Date of Patent: April 5, 2022Assignee: PANASONIC INTELLECTUAL PROPERTY MANAGEMENT CO., LTD.Inventor: Emina Ikeuchi